The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

  title={The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.},
  author={Y. F. Hsiou and J. P. Ding and Kalyan Das and Arthur D. Clark and Paul L. Boyer and Paul J. Lewi and Paul A. J. Janssen and J. P. Kleim and Manfred Dr. R{\"o}sner and Stephen H. Hughes and Eddy Arnold},
  journal={Journal of molecular biology},
  volume={309 2},
Inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT) are widely used in the treatment of HIV infection. Loviride (an alpha-APA derivative) and HBY 097 (a quinoxaline derivative) are two potent non-nucleoside RT inhibitors (NNRTIs) that have been used in human clinical trials. A major problem for existing anti-retroviral therapy is the emergence of drug-resistant mutants with reduced susceptibility to the inhibitors. Amino acid residue 103 in the p66 subunit of HIV-1 RT is… 

Figures and Tables from this paper

Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses

Analysis of the polymerase, connection, and RNase H domains of RT in HIV-2 patients failing NRTI-containing therapies shows that V111I does not strongly affect drug susceptibility but increases the replication capacity of the K65R and Q151M viruses.

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance

The first crystal structure of FIV RT is reported and, being the first structure of an RT from a non-primate lentivirus, it demonstrates that while the NNRTI binding pocket is conserved, minor subtleties at the entryway can render the Fiv RT pocket more restricted and unfavorable for effective NN RTI binding.

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase

The combined use of structural biology and biochemical approaches has led to the discovery of novel mechanisms of drug resistance and has contributed to the design of new drugs with improved potency and ability to suppress multi-drug resistant strains.

Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase Inhibitors

The characteristics of second-generation NNRTIs, including etravirine, rilpivirines, RDEA-806, UK-453061, BIRL 355 BS, IDX 899, MK-4965 and HBY 097 are reviewed.

Mechanistic insights into the role of secondary mutations of HIV-1 reverse transcriptase in the acquisition of antiretroviral drug resistance

The molecular mechanisms that facilitate the selection of mutations associated with TAMs during treatment with antiretroviral drugs are determined and predict that in the presence of NNRTIs, fitness differences between virus carrying the wild-type enzyme and the double-mutant N348I/T369I RT should be reduced.

Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.

Recent knowledge on drug-resistance mutations within HIV reverse transcriptase (RT) is summarized, including mutations in the HIV-1 RT C-terminal region, including the connection subdomain and RNase H domain, whose clinical impacts are still controversial.

Quantum Chemical Study of Molecular Recognition between Etravirine/Rilpivirine and the HIV-1 Reverse Transcriptase

The results of this study enhanced the understanding of the molecular level mechanisms by which the second generation NNRTI drugs maintain their strong binding to mutant RTs.

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

H BY 097 binds to the mutant RT in a manner similar to that seen in the wild-type RT/HBY 097 complex, although there are some repositioning and conformational alterations of the inhibitor, suggesting that inhibitor flexibility can help to minimize drug resistance.

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.

  • S. SarafianosK. Das E. Arnold
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
A model is developed that explains the ability of the 3TC-resistant mutant M184I to incorporate dNTPs but not the nucleotide analog 3TCTP and can also explain the 3 TC resistance of analogous hepatitis B polymerase mutants.

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

The structure of HIV-1 reverse transcriptase (RT) complexed with the nonnucleoside inhibitor TIBO R 86183 at 3.0 Å resolution is reported to provide a basis for understanding the nature of nonn DNA inhibitor binding, the structure of the binding site and the interactions between the bound inhibitors and surrounding amino acid residues.

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.

  • J. RenR. Esnouf D. Stammers
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1998
The crystal structures of AZT- and ddI-resistant RTs have been determined and it is likely that long-range effects at the RT polymerase site mediated simply by the protein could represent a common mechanism for generating drug resistance in other systems.

Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.

Two analogues of the nonnucleoside inhibitor of HIV-1 RT, MKC-442 (emivirine), containing different C6 substituents have been designed to be less susceptible to the commonly found drug-resistance